WHO establishes biomanufacturing training hub in South Korea

Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub

Bayer highlights pharma business plans on Media Day

Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)

Prestige BioPharma’s Tuznue receives EU-GMP certification

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue

Moderna expands Its mRNA pipeline with new development programs

These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.

USFDA accepts Mirati Therapeutics' New Drug Application for Adagrasib

The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022

Sandoz launches generic lenalidomide in 19 countries across Europe

Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines

Ribon Therapeutics appoints Prakash Raman as President and CEO

Dr. Raman has succeeded Victoria Richon

Bayer raises peak sales for Nubeqa to exceed €3 billion

Darolutamide is developed jointly by Bayer and Orion Corporation

USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi

Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years